ASX:TLXBiotechs
A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent FDA And Pipeline Milestones
Telix Pharmaceuticals (ASX:TLX) is back in focus after the FDA accepted its resubmitted New Drug Application for brain imaging agent Pixclara and the company reaffirmed its FY2026 revenue guidance alongside several late stage pipeline updates.
See our latest analysis for Telix Pharmaceuticals.
At A$14.52, Telix’s stock has given investors a 59.91% 90 day share price return and a 27.82% year to date share price return, yet the 1 year total shareholder return is down 43.19%, so near term...